Skip to main content
Top
Published in: Inflammation 3/2021

01-06-2021 | Original Article

Focal Adhesion Kinase Activity and Localization is Critical for TNF-α-Induced Nuclear Factor-κB Activation

Authors: James M. Murphy, Kyuho Jeong, Donna L. Cioffi, Pamela Moore Campbell, Hanjoong Jo, Eun-Young Erin Ahn, Ssang-Taek Steve Lim

Published in: Inflammation | Issue 3/2021

Login to get access

Abstract

While sustained nuclear factor-κB (NF-κB) activation is critical for proinflammatory molecule expression, regulators of NF-κB activity during chronic inflammation are not known. We investigated the role of focal adhesion kinase (FAK) on sustained NF-κB activation in tumor necrosis factor-α (TNF-α)–stimulated endothelial cells (ECs) both in vitro and in vivo. We found that FAK inhibition abolished TNF-α-mediated sustained NF-κB activity in ECs by disrupting formation of TNF-α receptor complex-I (TNFRC-I). Additionally, FAK inhibition diminished recruitment of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and the inhibitor of NF-κB (IκB) kinase (IKK) complex to TNFRC-I, resulting in elevated stability of IκBα protein. In mice given TNF-α, pharmacological and genetic FAK inhibition blocked TNF-α-induced IKK-NF-κB activation in aortic ECs. Mechanistically, TNF-α activated and redistributed FAK from the nucleus to the cytoplasm, causing elevated IKK-NF-κB activation. On the other hand, FAK inhibition trapped FAK in the nucleus of ECs even upon TNF-α stimulation, leading to reduced IKK-NF-κB activity. Together, these findings support a potential use for FAK inhibitors in treating chronic inflammatory diseases.
Appendix
Available only for authorised users
Literature
12.
13.
go back to reference Schlaepfer, D.D., S. Hou, S.T. Lim, A. Tomar, H. Yu, Y. Lim, D.A. Hanson, S.A. Uryu, J. Molina, and S.K. Mitra. 2007. Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression. The Journal of Biological Chemistry 282 (24): 17450–17459.CrossRef Schlaepfer, D.D., S. Hou, S.T. Lim, A. Tomar, H. Yu, Y. Lim, D.A. Hanson, S.A. Uryu, J. Molina, and S.K. Mitra. 2007. Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression. The Journal of Biological Chemistry 282 (24): 17450–17459.CrossRef
24.
go back to reference Nelson, D.E., A.E. Ihekwaba, M. Elliott, J.R. Johnson, C.A. Gibney, B.E. Foreman, G. Nelson, V. See, C.A. Horton, D.G. Spiller, S.W. Edwards, H.P. McDowell, J.F. Unitt, E. Sullivan, R. Grimley, N. Benson, D. Broomhead, D.B. Kell, and M.R. White. 2004. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306 (5696): 704–708. https://doi.org/10.1126/science.1099962.CrossRefPubMed Nelson, D.E., A.E. Ihekwaba, M. Elliott, J.R. Johnson, C.A. Gibney, B.E. Foreman, G. Nelson, V. See, C.A. Horton, D.G. Spiller, S.W. Edwards, H.P. McDowell, J.F. Unitt, E. Sullivan, R. Grimley, N. Benson, D. Broomhead, D.B. Kell, and M.R. White. 2004. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306 (5696): 704–708. https://​doi.​org/​10.​1126/​science.​1099962.CrossRefPubMed
29.
33.
34.
go back to reference Jeong, K., J.H. Kim, J.M. Murphy, H. Park, S.J. Kim, Y.A.R. Rodriguez, H. Kong, C. Choi, J.L. Guan, J.M. Taylor, T.M. Lincoln, W.T. Gerthoffer, J.S. Kim, E.E. Ahn, D.D. Schlaepfer, and S.S. Lim. 2019. Nuclear focal adhesion kinase controls vascular smooth muscle cell proliferation and neointimal hyperplasia through GATA4-mediated cyclin D1 transcription. Circulation Research 125 (2): 152–166. https://doi.org/10.1161/CIRCRESAHA.118.314344.CrossRefPubMedPubMedCentral Jeong, K., J.H. Kim, J.M. Murphy, H. Park, S.J. Kim, Y.A.R. Rodriguez, H. Kong, C. Choi, J.L. Guan, J.M. Taylor, T.M. Lincoln, W.T. Gerthoffer, J.S. Kim, E.E. Ahn, D.D. Schlaepfer, and S.S. Lim. 2019. Nuclear focal adhesion kinase controls vascular smooth muscle cell proliferation and neointimal hyperplasia through GATA4-mediated cyclin D1 transcription. Circulation Research 125 (2): 152–166. https://​doi.​org/​10.​1161/​CIRCRESAHA.​118.​314344.CrossRefPubMedPubMedCentral
35.
go back to reference Hirt, U.A., I.C. Waizenegger, N. Schweifer, C. Haslinger, D. Gerlach, J. Braunger, U. Weyer-Czernilofsky, H. Stadtmuller, I. Sapountzis, G. Bader, A. Zoephel, B. Bister, A. Baum, J. Quant, N. Kraut, P. Garin-Chesa, and G.R. Adolf. 2018. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis 7 (2): 21. https://doi.org/10.1038/s41389-018-0032-z.CrossRefPubMedPubMedCentral Hirt, U.A., I.C. Waizenegger, N. Schweifer, C. Haslinger, D. Gerlach, J. Braunger, U. Weyer-Czernilofsky, H. Stadtmuller, I. Sapountzis, G. Bader, A. Zoephel, B. Bister, A. Baum, J. Quant, N. Kraut, P. Garin-Chesa, and G.R. Adolf. 2018. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis 7 (2): 21. https://​doi.​org/​10.​1038/​s41389-018-0032-z.CrossRefPubMedPubMedCentral
36.
go back to reference Soria, J.C., H.K. Gan, S.P. Blagden, R. Plummer, H.T. Arkenau, M. Ranson, T.R. Evans, G. Zalcman, R. Bahleda, A. Hollebecque, C. Lemech, E. Dean, J. Brown, D. Gibson, V. Peddareddigari, S. Murray, N. Nebot, J. Mazumdar, L. Swartz, K.R. Auger, R.A. Fleming, R. Singh, and M. Millward. 2016. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology 27 (12): 2268–2274. https://doi.org/10.1093/annonc/mdw427.CrossRefPubMed Soria, J.C., H.K. Gan, S.P. Blagden, R. Plummer, H.T. Arkenau, M. Ranson, T.R. Evans, G. Zalcman, R. Bahleda, A. Hollebecque, C. Lemech, E. Dean, J. Brown, D. Gibson, V. Peddareddigari, S. Murray, N. Nebot, J. Mazumdar, L. Swartz, K.R. Auger, R.A. Fleming, R. Singh, and M. Millward. 2016. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology 27 (12): 2268–2274. https://​doi.​org/​10.​1093/​annonc/​mdw427.CrossRefPubMed
37.
go back to reference Jones, S.F., L.L. Siu, J.C. Bendell, J.M. Cleary, A.R. Razak, J.R. Infante, S.S. Pandya, P.L. Bedard, K.J. Pierce, B. Houk, W.G. Roberts, S.M. Shreeve, and G.I. Shapiro. 2015. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs 33 (5): 1100–1107. https://doi.org/10.1007/s10637-015-0282-y.CrossRefPubMed Jones, S.F., L.L. Siu, J.C. Bendell, J.M. Cleary, A.R. Razak, J.R. Infante, S.S. Pandya, P.L. Bedard, K.J. Pierce, B. Houk, W.G. Roberts, S.M. Shreeve, and G.I. Shapiro. 2015. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs 33 (5): 1100–1107. https://​doi.​org/​10.​1007/​s10637-015-0282-y.CrossRefPubMed
38.
go back to reference de Jonge, M.J.A., N. Steeghs, M.P. Lolkema, S.J. Hotte, H.W. Hirte, D.A.J. van der Biessen, A.R. Abdul Razak, F. De Vos, R.B. Verheijen, D. Schnell, L.C. Pronk, M. Jansen, and L.L. Siu. 2019. Phase I Study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies. Targeted Oncology 14 (1): 43–55. https://doi.org/10.1007/s11523-018-00617-1.CrossRefPubMedPubMedCentral de Jonge, M.J.A., N. Steeghs, M.P. Lolkema, S.J. Hotte, H.W. Hirte, D.A.J. van der Biessen, A.R. Abdul Razak, F. De Vos, R.B. Verheijen, D. Schnell, L.C. Pronk, M. Jansen, and L.L. Siu. 2019. Phase I Study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies. Targeted Oncology 14 (1): 43–55. https://​doi.​org/​10.​1007/​s11523-018-00617-1.CrossRefPubMedPubMedCentral
40.
go back to reference Tavora, B., L.E. Reynolds, S. Batista, F. Demircioglu, I. Fernandez, T. Lechertier, D.M. Lees, P.P. Wong, A. Alexopoulou, G. Elia, A. Clear, A. Ledoux, J. Hunter, N. Perkins, J.G. Gribben, and K.M. Hodivala-Dilke. 2014. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 514 (7520): 112–116. https://doi.org/10.1038/nature13541.CrossRefPubMedPubMedCentral Tavora, B., L.E. Reynolds, S. Batista, F. Demircioglu, I. Fernandez, T. Lechertier, D.M. Lees, P.P. Wong, A. Alexopoulou, G. Elia, A. Clear, A. Ledoux, J. Hunter, N. Perkins, J.G. Gribben, and K.M. Hodivala-Dilke. 2014. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 514 (7520): 112–116. https://​doi.​org/​10.​1038/​nature13541.CrossRefPubMedPubMedCentral
Metadata
Title
Focal Adhesion Kinase Activity and Localization is Critical for TNF-α-Induced Nuclear Factor-κB Activation
Authors
James M. Murphy
Kyuho Jeong
Donna L. Cioffi
Pamela Moore Campbell
Hanjoong Jo
Eun-Young Erin Ahn
Ssang-Taek Steve Lim
Publication date
01-06-2021
Publisher
Springer US
Published in
Inflammation / Issue 3/2021
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-020-01408-5

Other articles of this Issue 3/2021

Inflammation 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine